2024
Sample size and power calculation for testing treatment effect heterogeneity in cluster randomized crossover designs
Wang X, Chen X, Goldfeld K, Taljaard M, Li F. Sample size and power calculation for testing treatment effect heterogeneity in cluster randomized crossover designs. Statistical Methods In Medical Research 2024, 33: 1115-1136. PMID: 38689556, PMCID: PMC11347095, DOI: 10.1177/09622802241247736.Peer-Reviewed Original ResearchCluster randomized crossover designSample size formulaTreatment effect heterogeneityAverage treatment effectHeterogeneity of treatment effectsSize formulaRandomized crossover designCluster-randomized crossover trialRandomized crossover trialEffect heterogeneitySampling schemeCluster randomized designTreatment effectsDifferential treatment effectsCrossover designFormulaContinuous outcomesLinear mixed modelsSample sizeCrossover trialInteraction testMixed modelsCovariatesClinical characteristicsStatistical methods
2022
Designing three-level cluster randomized trials to assess treatment effect heterogeneity
Li F, Chen X, Tian Z, Esserman D, Heagerty PJ, Wang R. Designing three-level cluster randomized trials to assess treatment effect heterogeneity. Biostatistics 2022, 24: 833-849. PMID: 35861621, PMCID: PMC10583727, DOI: 10.1093/biostatistics/kxac026.Peer-Reviewed Original ResearchBlood pressure response to commonly administered antihypertensives for severe inpatient hypertension
Ghazi L, Li F, Chen X, Simonov M, Yamamoto Y, Biswas A, Hanna J, Shah T, Peixoto AJ, Wilson FP. Blood pressure response to commonly administered antihypertensives for severe inpatient hypertension. PLOS ONE 2022, 17: e0265497. PMID: 35385506, PMCID: PMC8985959, DOI: 10.1371/journal.pone.0265497.Peer-Reviewed Original ResearchConceptsHTN developmentSevere hypertensionOral hydralazineOral carvedilolIntensive care unit patientsBlood pressure elevationCare unit patientsAssociation of treatmentSingle healthcare systemAntihypertensive treatmentCommon antihypertensivesInpatient hypertensionOral amlodipinePrescribed antihypertensivesOral metoprololClinical characteristicsCohort studyUnit patientsBP responseHospitalized patientsPressure elevationBP changesLower BPHypertensionHydralazine